A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.

NCT00002199 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

550

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Indinavir sulfate
DRUG: Lamivudine/Zidovudine
DRUG: Abacavir sulfate

Sponsor

Glaxo Wellcome